For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
The current state of pharmaceutical tariffs
Background Amid the Trump trade upheaval, pharmaceutical products receive different treatment than many other US imports. Pharmaceuticals are treated differently for reasons such as their…
DC Journal
Point: Medicaid Work Requirements Are a Common-Sense Reform
Medicaid is the government program that is supposed to help the poor afford health care. Its cost to taxpayers has skyrocketed in the last few…
Blog
Congress considers micromanaging PBM finances
With the first reconciliation bill behind it, Congress is now looking to reform other aspects of the health care system. Pharmacy Benefit Manager (PBM)…
Search Posts
Blog
This week in ridiculous regulations: Blood donations to mortality tables
Poland voted its nationalist-populist government out of power. The US House of Representatives remained without a speaker, but with a lot of drama. Agencies issued…
City Journal
Equity vs. Evidence
The U.S. Preventive Services Task Force—a volunteer panel of national experts in prevention and evidence-based medicine that makes recommendations for clinical preventive services such as…
National Review
Restricting Pharmacy Benefit Managers Could Decrease Competition and Increase Drug Costs
Congress is considering multiple bills that aim to restrict the ability of pharmacy benefit managers (PBMs) to negotiate discounts and rebates and to require the PBMs…
PCMA
Just the Facts: Research and Analysis Finds Anti-PBM Legislation Does Not Lower Prescription Drug Costs for Patients
PCMA cites CEI’s Joel Zinberg anti PBM legislation: “This policy would significantly change drug pricing and utilization and shift billions of dollars annually from patients…
Wall Street Journal
Court to FDA: Stop Playing Doctor
The Food and Drug Administration regulates pharmaceuticals, but it has no business playing doctor and giving you medical advice. That’s the message of a Sept.
News Release
Congressional Efforts to Regulate PBMs Risk Higher Drug Costs, Worse Health Outcomes for Patients
Pharmacy Benefit Managers (PBMs) are private businesses that developed in the free market to manage prescription drug benefits for health insurance plan sponsors. Nearly all…
